PharosiBio

The company's business model is centered on its AI platform, Chemiverse, which utilizes deep learning algorithms and a massive dataset of over 240 million protein structures and compounds. Pharos iBio's strategy involves an open innovation approach, forming collaborations and partnerships to advance its drug pipeline. This allows the company to retain core functions and rights while scaling its infrastructure. Revenue generation is anticipated through technology out-licensing and co-development of its drug candidates. The firm primarily serves the biopharmaceutical market, with a focus on oncology and rare diseases. Pharos iBio is a publicly-traded company, having launched its Initial Public Offering (IPO) on the KOSDAQ in July 2023, raising KRW 19.6 billion.

The company's pipeline includes several drug candidates for various cancers. Its lead product, PHI-101, is a targeted anticancer drug for Acute Myeloid Leukemia (AML) and is also being investigated for platinum-resistant ovarian cancer and triple-negative breast cancer. PHI-101 targets the FLT3 gene mutation, which is present in a significant percentage of AML patients and is associated with a poorer prognosis. In a notable achievement, the company received approval for the therapeutic use of PHI-101 for an individual AML patient in South Korea, demonstrating the clinical application of its AI-developed drug. Other candidates in the pipeline include PHI-501 for malignant melanoma and refractory colorectal cancer, and PHI-201 for pancreatic and non-small cell lung cancer. The company has established subsidiaries in the US and Australia to further its global reach and collaborative efforts.